Basic science focus on blood substitutes: a summary of the NHLBI division of blood diseases and resources working group workshop, March 1, 2006

被引:31
作者
Estep, Timothy
Bucci, Enrico
Farmer, Martha
Greenburg, Gerson
Harrington, John
Kim, Hae Won
Klein, Harvey
Mitchell, Phyllis
Nemo, George
Olsen, Ken
Palmer, Andre
Valeri, C. Robert
Winslow, Robert
机构
[1] NHLBI, Div Blood Dis & Resources, Bethesda, MD 20892 USA
[2] Chart Biotech Consulting LLC, Erie, CO USA
[3] Univ Maryland, Sch Med, Dept Biochem & Biol, Baltimore, MD 21201 USA
[4] Harvard Univ, Sch Med, Dept Social Med, Boston, MA 02115 USA
[5] Brown Univ, Dept Surg, Providence, RI 02912 USA
[6] Biopure Corp, Cambridge, MA USA
[7] SUNY Albany, Sch Sci & Engn, New Paltz, NY 12561 USA
[8] NHLBI, Div Blood Dis & Resources, Bethesda, MD 20892 USA
[9] NHLBI, Dept Transfus Med, NIH, Bethesda, MD 20892 USA
[10] NHLBI, Blood Resources Program, Div Blood Dis & Resources, Bethesda, MD 20892 USA
[11] Loyola Univ, Dept Chem, Chicago, IL 60626 USA
[12] Ohio State Univ, Dept Chem & Biomol Engn, Columbus, OH 43210 USA
[13] Naval Blood Res Lab, Plymouth, Devon, England
[14] Sangart Inc, San Diego, CA USA
关键词
D O I
10.1111/j.1537-2995.2007.01604.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In March 2006, a workshop sponsored by the National Heart, Lung, and Blood Institute was convened to identify the role of basic science research in clarifying issues that are impeding progress in the development of hemoglobin-based oxygen carrying (HBOC) solutions. These discussions resulted in a consensus that, although HBOCs have shown clinical promise, various side effects have inhibited further development and regulatory approval, with cardiovascular events being of particular concern. As a consequence, workshop participants focused on formulating research recommendations to better understand and mitigate these side effects. In addition, several important corollary issues were identified, including better understanding of the impact of HBOC infusion on human physiology; the need for rapid, noninvasive methods for the measurement of tissue oxygenation in human patients to better inform transfusion decisions; further investigation of routes and consequences of hemoglobin metabolism; optimization of clinical protocols for HBOC use; and assessment of the impact of HBOC formulation excipients. Also discussed was the possibility and desirability of developing new HBOCs with improved characteristics, such as prolonged functional intravascular persistence, greater stability, and a decreased propensity to generate reactive oxygen species. One practical limitation in this area is the consistent availability of pure, well-characterized HBOC solutions for the research community. This communication summarizes the opinion of workshop participants on these issues and concludes with a list of specific recommended areas of research that could positively impact the development of blood substitutes.
引用
收藏
页码:776 / 782
页数:7
相关论文
共 19 条
  • [1] [Anonymous], 2001, Blood safety and surveillance
  • [2] Deleterious clinical effects of transfusion immunomodulation: proven beyond a reasonable doubt
    Blumberg, N
    [J]. TRANSFUSION, 2005, 45 (02) : 33S - 39S
  • [3] FRATANTONI JC, 1994, TRANSFUSION, V34, P712
  • [4] GOODNOUGH LT, 2005, CLIN N AM, V2, P241
  • [5] Clinical utility of human polymerized hemoglobin as a blood substitute after acute trauma and urgent surgery
    Gould, SA
    Moore, EE
    Moore, FA
    Haenel, JB
    Burch, JM
    Sehgal, H
    Sehgal, L
    DeWoskin, R
    Moss, GS
    [J]. JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 1997, 43 (02) : 325 - 331
  • [6] The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery
    Gould, SA
    Moore, EE
    Hoyt, DB
    Burch, JM
    Haenel, JB
    Garcia, J
    DeWoskin, R
    Moss, GS
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 1998, 187 (02) : 113 - 120
  • [7] GREENBURG A, 2006, ARTIF CELLS BLOOD SU, V34
  • [8] Greenburg AG, 2004, J AM COLL SURGEONS, V198, P373, DOI 10.1016/j.jamcollsurg.2003.11.020
  • [9] GREENBURG AG, 2007, ARTIF CELLS BLOOD SU, V35
  • [10] JAHR J, 2002, SOC CRIT CAR MED M S